Roche Holding AGXSWX:ROP +2.09%79 Current Ratio is 1.38 as of Dec. 2025, which is 4% above its 10-year median of 1.33. GuruFocus rates XSWX:ROP with a GF Score™ of 79/100 and a GF Value™ of CHF264.69 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 998 Drug Manufacturers companies, Roche Holding AG ranks worse than 69.64% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Roche Holding AG's current ratio for the quarter that ended in Dec. 2025 was 1.38.
Roche Holding AG has a current ratio of 1.38. It generally indicates good short-term financial strength.
The historical rank and industry rank for Roche Holding AG's Current Ratio or its related term are showing as below:
XSWX:ROP'
s Current Ratio Range Over the Past 10 Years
Min: 0.93 Med: 1.33 Max: 1.48
Current: 1.38
During the past 13 years, Roche Holding AG's highest Current Ratio was 1.48. The lowest was 0.93. And the median was 1.33.
XSWX:ROP's Current Ratio is ranked worse than 69.64% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs XSWX:ROP: 1.38
Roche Holding AG (XSWX:ROP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Roche Holding AG Current Ratio Related Terms
Roche Holding AG Current Ratio Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ROP vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (XSWX:ROP) has a Current Ratio of 1.38 as of Dec. 2025. This is near median its historical median of 1.33. Over the past decade, Roche Holding AG's Current Ratio has ranged from 0.93 to 1.48. According to the industry distribution chart, Roche Holding AG ranks #695 out of 998 companies in the Drug Manufacturers industry, placing it in the top 69.6%.
Is Roche Holding AG's Current Ratio too high?
Roche Holding AG's current Current Ratio of 1.38 is near median its 10-year median of 1.33. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 1.48. The Drug Manufacturers industry median Current Ratio is 2.00. Roche Holding AG's value of 1.38 is 30.8% below this industry median. Based on the distribution chart, Roche Holding AG ranks #695 out of 998 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #695 out of 998 companies for Current Ratio. This places Roche Holding AG in the lower half of its industry. The industry median Current Ratio is 2.00. Roche Holding AG's value of 1.38 is 30.8% below this benchmark. Historically, Roche Holding AG's own Current Ratio has ranged from 0.93 to 1.48 over the past decade. While the company's 10-year median is 1.33 vs. the industry median of 2.00, Roche Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current Current Ratio of 1.38 is 30.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current Current Ratio is 1.38, which is near median its own 10-year median of 1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.69, compared to a current price of CHF332.00 — trading 25.4% above its estimated fair value. The current Current Ratio is 1.38, which is near median its 10-year median of 1.33 and 30.8% below the Drug Manufacturers industry median of 2.00. Roche Holding AG's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current Current Ratio is 1.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF332.00 is trading 25.4% above its estimated GF Value™ of CHF264.69.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:ROP:
Current Ratio: 1.38 (near median its 10-year median of 1.33)
GF Value™: CHF264.69 vs. price of CHF332.00 (25.4% above fair value)
Industry Position: 30.8% below the Drug Manufacturers median (#695 of 998)
No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
79GF Score
Get the complete analysis for XSWX:ROP
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ROP has been successfully added to your 
